being was recognized by 57.2% to 79.3% of physicians. In patients with moderate-to-severe psoriasis, dermatologists reported 74.9% were receiving topical therapy, 19.5% conventional oral therapy and 19.6% biologics. Dermatologists and rheumatologists reported similar rates of topical (≈45%) and biologic (≈30%) therapy utilization for their PsA patients; conventional oral therapy was more often prescribed by rheumatologists (63.4%) vs. dermatologists (35.2%). Reasons for not initiating or maintaining systemic therapies were related to concerns about long-term safety, tolerability, efficacy and costs (biologics). Physicians in North America and Europe caring for patients with psoriasis and PsA acknowledge unmet treatment needs, largely concerning long-term safety/tolerability and efficacy of currently available therapies; evidence suggests underdiagnosis of PsA and undertreatment of psoriasis among dermatologists. Current published estimates of the worldwide prevalence of psoriasis range from approximately 1–3%.1-6 Psoriatic arthritis (PsA) occurs in approximately 10–30% of psoriasis patients. In the vast majority of cases, joint involvement follows skin involvement, often by 10 years.7, 8 Patients with psoriasis and PsA experience a significant burden of disease, including reduced quality of life, decreased physical function and increased comorbidities.7, 9, 10 Available evidence suggests that numerous unmet needs exist in the care of these patients, including underdiagnosis2, 7 and suboptimal treatment. Available surveys offer insight into psoriasis and PsA disease burden and treatment. However, most are limited to a specific geographic region, patients currently under the care of a physician and/or being treated in a specific healthcare setting and/or members of a patient association, or lack of both a patient and physician survey component. Moreover, many surveys provide limited information on patient- and physician-related factors influencing treatment decisions. To better understand the unmet needs from the patient and physician perspective, and to gain deeper insight into the impact of psoriasis and PsA on patients' lives, a population-based survey of 4400 patients and 800 physicians in North America and Europe was conducted. The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey is the first-of-its-kind, large-scale, multinational survey conducted. The survey explores the diagnosis and impact of psoriasis and PsA on health-related quality of life as well as attitudes towards current therapies. The MAPP survey was developed with patient and physician input and aims to provide a better reflection of psoriasis and PsA severity, including the impact of disease and its treatment on patients' daily lives from the physician perspective. Results from the multinational patient survey, published separately, identified unmet needs related to assessment of disease severity, PsA screening and diagnosis and treatment options.8 The current report includes results from the multinational physician survey. The survey was conducted by Abt SRBI, Inc (New York, NY, USA). Methodology and results of the patient survey have been reported.8 Dermatologists and rheumatologists were identified through national databases for each country. Physicians were contacted from this list through random sampling methods and offered participation in the survey. Screening criteria for dermatologists required that ≥ 50% of their practice be devoted to